ClinicalTrials.gg
RecruitingNCT07029243Updated Jul 15, 2026

Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

An interventional study of HEAL-ME digital app and Creatine supplementation in Cirrhosis, Frailty and Sarcopenia, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Primary conditionFrailtyRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Frailty
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Frailty.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 185 studies in Frailty with a site in United States — 48 open to participants now, 61 under way, 1 of them phase 3. Frailty · United States.

Planned enrollment
36th of 142
100 · median 42
Started
2026
with 7 others
No phase
93 of 185
27 open now
Primary completion
2026-12
later than 26 of 59 live
Registered
172nd of 185
by date
Lead sponsor
5 of 185
University of California, San Francisco

Among the 185 studies in Frailty with a site in United States, this one is the 36th largest by planned enrollment of the 142 interventional ones that give a count, is one of 8 that started in 2026, is one of 93 with no phase, reaches primary completion later than 26 of the 59 other live ones, and was the 172nd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

48 of the 185 studies in Frailty with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Frailty with a site in United States, or all of them as a file.
02

Study summary

Frailty and muscle health are important for patients with chronic liver disease. This study looks at the use of a digital prehabilitation app (HEAL-ME) plus creatine and whey protein combination supplementation on maintaining muscle health in patients with liver disease. The investigators anticipate that this combination of supplementation and nutrition/exercise prehabilitation app will maintain muscle health in patients with liver disease.

03

Conditions studied

  • Cirrhosis
  • Frailty
  • Sarcopenia

Browse trials for

Keywords

  • cirrhosis
  • liver
  • muscle
  • creatine
  • whey protein
  • frailty
04

In context

Frailty Reclassified

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 100 is above the median of 83 across 772 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.

Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.

Compared within Frailty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of cirrhosis by ICD-10 code, liver , abdominal imaging, or transient elastography
  • Access to digital device and internet at home
  • Ability to provide written before any study-related activities
  • Ability to remain in study for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Allergy to milk protein
  • On hemodialysis
  • No English language proficiency
  • Presence of condition or abnormality that in opinion of the Investigator will compromise safety of the patient or quality of the data
  • Concomitant severe underlying systemic illness that in the opinion of the Investigator would interfere with completion of study
  • Pregnant, breastfeeding, or intention of becoming pregnant during study time frame
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    HEAL-ME and placebo supplementation

    Patients within this arm will be administered the HEAL-ME digital app and placebo supplementation daily

    Behavioral: HEAL-ME digital app · Dietary Supplement: Placebo

  • Experimental
    HEAL-ME and creatine/whey protein supplementation

    Patients within this arm will be administered the HEAL-ME digital app and whey protein/creatine combination supplementation daily

    Behavioral: HEAL-ME digital app · Dietary Supplement: Creatine supplementation · Dietary Supplement: Whey protein supplementation

Interventions

  • BehavioralHEAL-ME digital app

    HEAL-ME is a digital prehabilitation app that provides semi-guided nutrition/exercise prehabilitation

    Also known as: exercise, nutrition

  • Dietary supplementCreatine supplementation

    Patients will take 5g creatine supplementation daily for 13 weeks

    Also known as: Creatine

  • Dietary supplementWhey ProteinsStudies of Whey ProteinsWhey Proteins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will take 35g whey protein supplementation daily

    Also known as: Whey

  • Dietary supplementPlacebo

    Patients will be administered daily placebo supplementation.

07

What researchers measure

Primary outcomes

  1. Frailty

    Frailty will be used to assess muscle quality. The liver frailty index (LFI) includes the measurement of grip strength, chair stands, and balance. The Liver Fraity Index typically ranges from 1.0 to 5.0 with the following cut-offs: Robust is Liver Frailty Index \<3.2, Pre-frail is Liver Frailty Index between 3.2 and 4.4, and Frail is Liver frailty Index ≥4.4. We will use the previously identified cut-off of ≥4.4 (frail) vs. \<4.4 (not frail) to identify frailty in this study.

    Time frame: From enrollment to end of study at 12 weeks

Secondary outcomes

  1. Feasibility: Completion Rate

    Completion rate will be assessed by study coordinators. Study coordinators will identify patients who do or do not complete the study during check-ins. Reasons for dropping out of the study will be recorded by study coordinators.

    Time frame: From study enrollment to end of study at 12 weeks

  2. Health-related quality of life (HRQOL)

    The Patient Reported Outcomes Measurement Information System (PROMIS)-29 v 2.0 is a NIH-supported effort to develop and disseminate patient-reported measures of HRQOL that has built-in normative reference to the US general population. The PROMIS-29 v2.0 will be used to assess HRQOL. A score ≤25 has been used to define the 25th percentile value for the general population and has previously been used in our studies to be considered poor HRQOL.

    Time frame: From enrollment to end of study at 12 weeks

  3. Self-Reported Physical Activity

    The Duke Activity Status Index (DASI) will be used to measure self-reported physical activity. The DASI questionnaire provides a score from 0 to 58.2 with higher scores indicating better functional status and lower score indicating worse functional status. DASI will be measured as a continuous variable

    Time frame: From enrollment to end of study at 12 weeks

  4. Sarcopenia

    Sarcopenia will be measured by abdominal computed tomography (CT) scan measured CT-quantified skeletal muscle index (skeletal muscle index (SMI) \<50 cm2/m2 for men and \<39 cm2/m2 for women). We have previously demonstrated that CT-quantified sarcopenia is associated with worse outcomes in patients with cirrhosis.

    Time frame: From enrollment to end of study at 12 weeks

  5. Feasibility: Adherence Rate

    Adherence rate will be assessed by study coordinators at each check-in. Adherence rate will include total adherence to the study protocol, adherence to supplement/placebo, and adherence to HEAL-ME activities.

    Time frame: From study enrollment to end of study at 12 weeks

  6. Feasibility: Patient Satisfaction

    Patient satisfaction will be assessed by study coordinators at the end of the study. Patient satisfaction will be reported as a scalar variable from 0 to 5.

    Time frame: From study enrollment to end of study at 12 weeks

08

Study locations

1 of 1 sites recruiting
  • University of California San Francisco
    San Francisco, California 94143, United States
    Recruiting
    • Melinda Wang, MD, MHS · Contactmelinda.wang3@ucsf.edu · 415-476-2777
    • Jennifer Lai, MD, MBA · Principal investigator
    • Melinda Wang, MD, MHS · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 8 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 19, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07029243
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Apr 15, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Melinda Wang, MD, MHS
Contact
melinda.wang3@ucsf.edu
415-476-2777
Jennifer Lai, MD, MBA
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Whey Proteins

Start the discussion